To examine coronary artery calcium (CAC) as a marker of subclinical atherosclerosis and its association with major adverse cardiovascular events (MACE) in patients with CRC across the cancer treatment trajectory.

We conducted a proteomic analysis of urinary extracellular vesicles (uEVs) to identify and validate new diagnostic markers for bladder cancer. Focusing on cytoplasmic EV proteins, we discovered EV-EIF2S1 as a novel marker and demonstrated its crucial role in the growth and survival of bladder cancer.

Analysis of primary AML cells from 46 patients shows significant variability in metabolic activity, highlighting diverse metabolic phenotypes within the disease. AML cells classified as FAB M4/M5 exhibited higher metabolic rates compared to less mature phenotypes. The findings underscore the potential for targeted therapeutic strategies based on specific metabolic profiles.

Lung volume as a part of pulmonary function test is often underrepresented in prognostic lung cancer research. In this longitudinal lung cancer patient cohort, higher residual volume to total lung capacity (RV/TLC) ratio upon diagnosis was associated with worse overall survival regardless of spirometry results or cancer stage. The findings provide first-line evidence for the prognostic value of lung volume measurements and lay the groundwork for future studies to clarify their role in lung cancer prognosis.

This study examined whether there were changes in the stage of diagnosis for breast and cervical cancers diagnosed among Utah women during the pandemic (January 2020–December 2021) compared to years prior to the pandemic (January 2018–December 2019). We saw a significant increase in the incidence of late-stage cervical cancer during the pandemic compared with pre-pandemic. Conversely, while local-stage breast cancer incidence was slightly lower during COVID-19 compared with pre-COVID-19, no difference was observed among all other stages.

Tertiary lymphoid structure (TLS) was an independent predictor of favorable prognosis in MIBC, and mainly played antitumor role effect through B cells. Through NGS analysis of tumor samples, we also believe that TP53 mutations could inhibit the formation of TLS.

Our data show for the first time that CRC tumors have expression of AKR1B1 in both epithelial and stromal compartments; moreover, the relationship of AKR1B1 expression and clinical outcome depends highly on the TME content.

This figure illustrates the proposed mechanism of NSD2 regulation in melanoma following romidepsin and interferon-α2b (RI) treatment. RI induces a de-differentiation process, particularly in proliferative melanoma cells, leading to NSD2 downregulation. This effect is mediated by the upregulation of specific miRNAs (miR-23a, miR-24, and miR-31), which target NSD2 and influence downstream oncogenic pathways involving CCND1, MYC, and BCL2.

GRB2 as a flexible protein and an RBP that is involved in post-transcriptional regulation in eukaryotes, influencing all stages of mRNA synthesis, modification, splicing, and stabilization.